Regulation of Muscle Mass by Follistatin and Activins
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Myostatin is a TGF-β family member that normally acts to limit skeletal muscle mass. Follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro and promote muscle growth in vivo. Mice homozygous for a mutation in the Fst gene have been shown to die immediately after birth but have a reduced amount of muscle tissue, consistent with a role for follistatin in regulating myogenesis. Here, we show that Fst mutant mice exhibit haploinsufficiency, with muscles of Fst heterozygotes having significantly reduced size, a shift toward more oxidative fiber types, an impairment of muscle remodeling in response to cardiotoxin-induced injury, and a reduction in tetanic force production yet a maintenance of specific force. We show that the effect of heterozygous loss of Fst is at least partially retained in a Mstn-null background, implying that follistatin normally acts to inhibit other TGF-β family members in addition to myostatin to regulate muscle size. Finally, we present genetic evidence suggesting that activin A may be one of the ligands that is regulated by follistatin and that functions with myostatin to limit muscle mass. These findings potentially have important implications with respect to the development of therapeutics targeting this signaling pathway to preserve muscle mass and prevent muscle atrophy in a variety of inherited and acquired forms of muscle degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have previously demonstrated that growth differentiation factor-8 (GDF8; also known as myostatin) and activin A (ActA) are the two major ligands mediating the muscle-minimization actions of ActRIIA/B receptors22,26–30.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The function of MSTN in muscle is at least partially redundant with that of another TGF-β family member, activin A (13–16).”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FST acts as an inhibitor of members of the TGF-β superfamily, including myostatin and activins [185,186], and can function as a promoter of skeletal muscle growth [187].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [187]
In the citing paper
“Both follistatin and GASPs inhibit the activities of GDF11 and myostatin; accordingly, follistatin (Fst)-heterozygous47 and Gasp1-null or Gasp2-null48 mice have smaller muscles and increased GDF11 and myostatin bioactivity.”
From The central role of muscle stem cells in regenerative failure with aging (2015) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Self-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Self-citationRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 3×
“Follistatin is a potent myostatin inhibitor that can cause dramatic increases in muscle mass when overexpressed as a transgene in mice (18, 21, 22).”
BackgroundSelf-citationA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Self-citationClop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Mutations in myostatin ( GDF8 ) in Double-Muscled Belgian Blue and Piedmontese Cattle
Kambadur, R., Sharma, M., Smith, T. P. L., & Bass, J. J. (1997) · Genome Research · doi:10.1101/gr.7.9.910 · Cited by 1,204
Efficient in vivo manipulation of mouse genomic sequences at the zygote stage.
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W., & Westphal, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5860 · Cited by 1,125 · cited 1×
“Mice carrying the targeted allele were crossed to EIIa-cre transgenic mice (33) to generate mice in which recombination had occurred between the outside LoxP sites (denoted by triangles), thereby resulting in a mutant allele in which exons 3–5 were completely deleted in the germline.”
MethodInduction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Self-citationThe regulation of TGFβ signal transduction
Moustakas, A., & Heldin, C.-H. (2009) · Development · doi:10.1242/dev.030338 · Cited by 832
Cited by
Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models
Schiaffino, S., & Mammucari, C. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-4 · Cited by 816
“In adult skeletal muscle, muscle hypertrophy can be induced and muscle wasting prevented by blocking myostatin either via postdevelopmental myostatin gene knockout, or with follistatin (a myostatin antagonist) or anti-myostatin antibodies or a soluble ActRIIB decoy receptor (see [19,20] and references therein).”
BackgroundGDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527
“, 2009), resulted in an even greater increase in muscle size (Lee et al., 2010).”
The central role of muscle stem cells in regenerative failure with aging
Blau, H. M., Cosgrove, B. D., & Ho, A. T. V. (2015) · Nature Medicine · doi:10.1038/nm.3918 · Cited by 437
Mechanisms for fiber-type specificity of skeletal muscle atrophy
Wang, Y., & Pessin, J. E. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328360272d · Cited by 414
Roberts, E. W., Deonarine, A., Jones, J. O., Denton, A. E., Feig, C., Lyons, S. K., Espeli, M., Kraman, M., McKenna, B., Wells, R. J. B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122344 · Cited by 414
“This is demonstrated by the comparison between the wasted Fst+/ mouse and the normal muscle mass of mice expressing only the Fst288 isoform (Lee et al., 2010; Brown et al., 2011).”
BackgroundMolecular and cellular mechanisms of skeletal muscle atrophy: an update
Fanzani, A., Conraads, V. M., Penna, F., & Martinet, W. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0074-6 · Cited by 370
“certain catabolic factors, including tumor necrosis factor alpha (TNFα) [33, 34], transforming growth factor beta (TGFβ) ligands such as myostatin [35–38] and glucocorticoids [39–42].”
BackgroundAtrogin-1, MuRF-1, and sarcopenia
Gumucio, J. P., & Mendias, C. L. (2013) · Endocrine · doi:10.1007/s12020-012-9751-7 · Cited by 370
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
TGF-β Family Signaling in Mesenchymal Differentiation
Grafe, I., Alexander, S., Peterson, J. R., Snider, T. N., Levi, B., Lee, B., & Mishina, Y. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022202 · Cited by 272
Garcia, L. A., King, K. K., Ferrini, M. G., Norris, K. C., & Artaza, J. N. (2011) · Endocrinology · doi:10.1210/en.2011-0159 · Cited by 263
“It has been demonstrated that Fst antagonizes Mstn by a direct protein interaction, preventing Mstn from executing its inhibitory effect on muscle development (37, 38).”
BackgroundHepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
“FST acts as an inhibitor of members of the TGF-b superfamily, including myostatin and activins [185,186], and can function as a promoter of skeletal muscle growth [187].”
BackgroundSkeletal Muscle Wasting and Renewal: A Pivotal Role of Myokine IL-6
Belizário, J. E., Fontes-Oliveira, C. C., Borges, J. P., Kashiabara, J. A., & Vannier, E. (2016) · SpringerPlus · doi:10.1186/s40064-016-2197-2 · Cited by 244
The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt, K. I., Thomson, R. E., Connor, T., Turner, B. J., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211134 · Cited by 225
“We found that in skeletal muscles expressing follistatin (via rAAV6:Fst-288 injection), a protein that promotes hypertrophy by preventing myostatin and activin from engaging activin receptors (Lee, 2007; Lee et al., 2010; Winbanks et al., 2012), Smad1/5 S463/465 phosphorylation was increased (Fig.”
Winbanks, C. E., Weeks, K. L., Thomson, R. E., Sepulveda, P. V., Beyer, C., Qian, H., Chen, J. L., Allen, J. M., Lancaster, G. I., Febbraio, M. A., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201109091 · Cited by 218
“However, the effects of Fst knockdown or transgenic overexpression upon muscle development can be recapitulated in myostatin-null mice (Lee, 2007; Lee et al., 2010).”
Activin A in Mammalian Physiology
Bloise, E., Ciarmela, P., Dela Cruz, C., Luisi, S., Petraglia, F., & Reis, F. M. (2019) · Physiological Reviews · doi:10.1152/physrev.00002.2018 · Cited by 199
“Furthermore, activin A operates in concert with GDF-8/myostatin, a more potent myogenic inhibitor, which also binds to and activates ActRIIB to restraint muscle mass overgrowth (219, 223).”
BackgroundResultActivin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185
TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease
Sartori, R., Gregorevic, P., & Sandri, M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.002 · Cited by 177
Mechanisms Limiting Body Growth in Mammals
Lui, J. C., & Baron, J. (2011) · Endocrine Reviews · doi:10.1210/er.2011-0001 · Cited by 169
Lee, S.-J., Huynh, T. V., Lee, Y.-S., Sebald, S. M., Wilcox-Adelman, S. A., Iwamori, N., Lepper, C., Matzuk, M. M., & Fan, C.-M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206410109 · Cited by 167
“In previous studies, we had shown that muscle growth is regulated by not only myostatin but by multiple members of the TGF-β family, including activin A (13, 20, 21).”
BackgroundSelf-citationRoles of nonmyogenic mesenchymal progenitors in pathogenesis and regeneration of skeletal muscle
Uezumi, A., Ikemoto-Uezumi, M., & Tsuchida, K. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00068 · Cited by 165
“Fst has been shown to inhibit other TGFβ family members in addition to myostatin to regulate muscle size (Lee, 2007; Lee et al., 2010).”
BackgroundSelf-citationMyostatin is associated with age‐related human muscle stem cell dysfunction
McKay, B. R., Ogborn, D. I., Bellamy, L. M., Tarnopolsky, M. A., & Parise, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-198663 · Cited by 163
Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps
Baczek, J., Silkiewicz, M., & Wojszel, Z. B. (2020) · Nutrients · doi:10.3390/nu12082401 · Cited by 156
“Follistatin, a single-chain glycosylated protein, is expressed in various tissues and antagonizes both myostatin and activin A activity, influencing their effects on muscle mass [115,116].”
BackgroundMarking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisions
Olguín, H. C., & Pisconti, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01348.x · Cited by 163
“Whether the downstream effects of follistatin are entirely dependent on inhibition of myostatin [138] or, at least in part, myostatin independent [139] requires further investigation.”
BackgroundTargeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S.-J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 143
“Studies in mice have shown that targeting MSTN alone is sufficient to induce muscle growth but that targeting MSTN along with other TGF-β family members, most notably activin A, can have a much greater effect (24, 26, 33, 40, 41), and this seems to have been borne out in the clinical trials as well.”
InfluentialSelf-citationStefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
Smad3 Induces Atrogin-1, Inhibits mTOR and Protein Synthesis, and Promotes Muscle Atrophy In Vivo
Goodman, C. A., McNally, R. M., Hoffmann, F. M., & Hornberger, T. A. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1194 · Cited by 138
“Interestingly, both TGF- and activin A are also implicated in skeletal muscle atrophy and fibrosis (21, 22).”
BackgroundMyostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135
Terada, S., Ota, S., Kobayashi, M., Kobayashi, T., Mifune, Y., Takayama, K., Witt, M. R., Vadalà, G., Oyster, N., Otsuka, T., et al. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.00266 · Cited by 141
Ragni, E., Orfei, C. P., Luca, P. D., Mondadori, C., Viganò, M., Colombini, A., & de Girolamo, L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01677-9 · Cited by 146
“Follistatin [46] is by far the most abundant (> 500 ng).”
Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting
Breitbart, A., Auger-Messier, M., Molkentin, J. D., & Heineke, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00200.2011 · Cited by 131
“Moreover, heterozygous activin-A knockout mice show increased skeletal muscle weights while overexpression of activin-A induces muscle atrophy (26, 42).”
BackgroundZhu, J., Li, Y., Lu, A., Gharaibeh, B., Ma, J., Kobayashi, T., Quintero, A., & Huard, J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.008 · Cited by 136
“It has been recently reported that activin A knockout mice exhibit significant size increases in both their pectoralis and triceps muscles, which provides genetic evidence that activin A may be one of the key growth factors that function in tandem with myostatin to limit muscle growth.(41) In this study, our results h…”
BackgroundMethodMyostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation
Wang, Q., & McPherron, A. C. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.226001 · Cited by 122
“Like MSTN, activin is also a ligand for this receptor and inhibits muscle growth (Amthor et al. 2002, 2006; Lee et al. 2010).”
BackgroundParker, C. C., Gopalakrishnan, S., Carbonetto, P., Gonzales, N. M., Leung, E., Park, Y. J., Aryee, E., Davis, J., Blizard, D. A., Ackert-Bicknell, C. L., et al. (2016) · Nature Genetics · doi:10.1038/ng.3609 · Cited by 121
“One of the genes in this interval, Fst, is known to influence muscle mass 28,29 and is a strong candidate to explain this association.”
Vitamin D in cancer chemoprevention
Giammanco, M., Di Majo, D., La Guardia, M., Aiello, S., Crescimannno, M., Flandina, C., Tumminello, F. M., & Leto, G. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2014.988274 · Cited by 119
“…shown to facilitate myogenic differentiation by increasing the expression of IGF-II and Follistatin (Lee et al., 2010) and by decreasing the expression of the insulin growth factor I (IGF-I) and that of myostatin, a negative regulator of skeletal muscle mass (Garcia et al., 2011; Lee et al., 2010).”
InfluentialCardiokines: recent progress in elucidating the cardiac secretome
Shimano, M., Ouchi, N., & Walsh, K. (2012) · Circulation · doi:10.1161/circulationaha.112.150656 · Cited by 116
Kwon, J. H., Moon, K. M., & Min, K.-W. (2020) · Healthcare · doi:10.3390/healthcare8040378 · Cited by 116
“Myostatin, inhibited by follistatin, has recently attracted attention as a useful pharmacological target for preserving muscle mass and preventing atrophy [186].”
BackgroundChen, J. L., Walton, K. L., Hagg, A., Colgan, T. D., Johnson, K., Qian, H., Gregorevic, P., & Harrison, C. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620013114 · Cited by 116
“(16) to suggest that activins may be the other ligands that are regulated by soluble ActRIIB and follistatin in muscle.”
BackgroundTargeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014716117 · Cited by 115
Self-citationLü, J., Hou, Y., Wu, H., Miao, Y., Li, X., Cao, J., Brameld, J. M., Parr, T., & Zhao, S. (2015) · Scientific Reports · doi:10.1038/srep11953 · Cited by 140
Follistatin Promotes Adipocyte Differentiation, Browning, and Energy Metabolism
Braga, M., Reddy, S. T., Vergnes, L., Pervin, S., Grijalva, V., Stout, D., David, J., Li, X., Tomasian, V., Reid, C. B., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m039719 · Cited by 111
A Novel Therapeutic Approach to Treating Obesity through Modulation of TGFβ Signaling
Koncarevic, A., Kajimura, S., Cornwall-Brady, M., Andreucci, A., Pullen, A., Sako, D., Kumar, R., Grinberg, A. V., Liharska, K., Ucran, J. A., et al. (2012) · Endocrinology · doi:10.1210/en.2012-1016 · Cited by 109
Muscular effects of vitamin D in young athletes and non-athletes and in the elderly
Koundourakis, N. E., Avgoustinaki, P. D., Malliaraki, N., & Margioris, A. N. (2016) · Hormones · doi:10.14310/horm.2002.1705 · Cited by 109
Dukes, A., Davis, C., El Refaey, M., Upadhyay, S., Mork, S., Arounleut, P., Johnson, M. H., Hill, W. D., Isales, C. M., & Hamrick, M. W. (2015) · Nutrition · doi:10.1016/j.nut.2015.02.011 · Cited by 105
“Follistatin is an important regulator of myofiber hypertrophy as it is a potent antagonist of both activin and myostatin, two factors known to be involved in the suppression of muscle growth and development [30].”
BackgroundmiR-431 promotes differentiation and regeneration of old skeletal muscle by targeting Smad4
Lee, K.-P., Shin, Y. J., Panda, A. C., Abdelmohsen, K., Kim, J. Y., Lee, S.-M., Bahn, Y. J., Choi, J. Y., Kwon, E.-S., Baek, S.-J., et al. (2015) · Genes & Development · doi:10.1101/gad.263574.115 · Cited by 104
Self-citationHofmann, M., Schober-Halper, B., Oesen, S., Franzke, B., Tschan, H., Bachl, N., Strasser, E.-M., Quittan, M., Wagner, K.-H., & Wessner, B. (2016) · European Journal of Applied Physiology · doi:10.1007/s00421-016-3344-8 · Cited by 102
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 101
“Physical exercise, directly or through indirect metabolic changes, such as low insulin-to-glucagon ratio, GH, and IGF1, enhances the synthesis of myokines and promotes the liver-mediated secretion of follistatin with a net effect on skeletal muscle gain [63,64].”
BackgroundHomeostatic regulation of protein intake: in search of a mechanism
Morrison, C. D., Reed, S. D., & Henagan, T. M. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00609.2011 · Cited by 99
Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness
Waning, D. L., & Guise, T. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1590 · Cited by 106
“Activin A has also been shown to function with Myostatin to reduce muscle size (56).”
BackgroundRegulation of GDF-11 and myostatin activity by GASP-1 and GASP-2
Lee, Y.-S., & Lee, S.-J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309907110 · Cited by 99
“In particular, loss of MSTN activity has been shown to result in an enhanced regenerative response to injury (27, 28), whereas heterozygous loss of Fst impaired muscle remodeling in response to injury (29).”
BackgroundSelf-citationEmerging drugs for Duchenne muscular dystrophy
Malik, V., Rodino-Klapac, L. R., & Mendell, J. R. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.691965 · Cited by 97
“The potency of this agent is significantly greater than myostatin blockade alone based on studies in mice demonstrating retained activity despite a myostatinnull background [66].”
BackgroundSmad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
“The comparatively diminished hypertrophic action of rAAV6:Smad7 in mice lacking myostatin is consistent with the fact that additional ActRIIB ligands (for example, activin and GDF11) act in concert with myostatin to negatively regulate muscle mass (18, 19).”
BackgroundWnt/β-catenin controls follistatin signalling to regulate satellite cell myogenic potential
Jones, A. E., Price, F. D., Le Grand, F., Soleimani, V. D., Dick, S. A., Megeney, L. A., & Rudnicki, M. A. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0038-6 · Cited by 90
“Strikingly, follistatin regulation remains functional in myostatin-null mice, suggesting a myostatinindependent function [54,55].”
BackgroundMyostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?
Suh, J., & Lee, Y. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.3.151 · Cited by 104
“In contrast, mice lacking FST,[45] GASP1, or GASP2 [46] display reduced muscle mass and impaired muscle regeneration, effects corresponding to hyperactivity of myostatin.”
BackgroundInfluentialSelf-citationVitamin D induces myogenic differentiation in skeletal muscle derived stem cells
Braga, M., Simmons, Z., Norris, K. C., Ferrini, M. G., & Artaza, J. N. (2017) · Endocrine Connections · doi:10.1530/ec-17-0008 · Cited by 95
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Self-citationMolecular insights of exercise therapy in disease prevention and treatment
Walzik, D., Chirino, T. Y. W., Zimmer, P., & Joisten, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01841-0 · Cited by 107
“Conversely, follistatin antagonizes these effects via sequestration of myostatin and other activins, thereby facilitating skeletal muscle hypertrophy 240 and improving insulin signaling in normal weight and obese mice.”
BackgroundAbati, E., Manini, A., Comi, G. P., & Corti, S. P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04408-w · Cited by 91
“For instance, there might be compensatory signaling through other related growth factors regulating muscle mass, such as follistatin, that might explain why less specific compounds display a higher efficacy [140].”
BackgroundPalstra, A. P., Rovira, M., Rizo‐Roca, D., Torrella, J. R., Spaink, H. P., & Planas, J. V. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-1136 · Cited by 97
“On one hand, we observed an increase in the mRNA levels of follistatin (fst), known to promote muscle hypertrophy in mammals by binding myostatin (MSTN) and preventing its interaction with activin receptors resulting in activation of the Akt/mTOR signaling pathway to stimulate protein synthesis [28].”
BackgroundRelative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments
Angelidi, A. M., Stefanakis, K., Chou, S. H., Valenzuela-Vallejo, L., Dipla, K., Boutari, C., Ntoskas, K., Tokmakidis, P., Kokkinos, A., Goulis, D. G., et al. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae011 · Cited by 83
Yan, X., Huang, Y., Jx, Z., Rogers, C. J., Zhu, M.-J., Ford, S. P., Nathanielsz, P. W., & Du, . (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.69 · Cited by 89
Sevivas, N., Teixeira, F. G., Portugal, R., Araújo, L., Carriço, L. F., Ferreira, N., Vieira da Silva, M., Espregueira-Mendes, J., Anjo, S., Manadas, B., et al. (2017) · The American Journal of Sports Medicine · doi:10.1177/0363546516657827 · Cited by 80
“The follistatin action represents a signaling pathway to preserve muscle mass and prevent muscle atrophy that can be used therapeutically in acquired forms of muscle degeneration.(25) The other protein identified in secretome, PEDF, has been proven to induce satellite cell proliferation and promote muscle regeneration.”
BackgroundMyostatin – The Holy Grail for Muscle, Bone, and Fat?
Buehring, B., & Binkley, N. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0160-5 · Cited by 79
Nawaz, A., Bilal, M., Fujisaka, S., Kado, T., Aslam, M. R., Ahmed, S., Okabe, K., Igarashi, Y., Watanabe, Y., Kuwano, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34191-y · Cited by 89
Self-citationDeep RNA Sequencing of the Skeletal Muscle Transcriptome in Swimming Fish
Palstra, A. P., Beltrán, S., Burgerhout, E., Brittijn, S. A., Magnoni, L. J., Henkel, C. V., Jansen, H. J., van den Thillart, G. E. E. J. M., Spaink, H. P., & Planas, J. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053171 · Cited by 94
“factor receptor alpha [19–26].”
Skeletal Muscle Regeneration in Cardiotoxin-Induced Muscle Injury Models
Wang, Y., Lu, J., & Liu, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113380 · Cited by 96
“Lee KP, 2015 Hindlimb muscle miR-431 Myoblast differentiation Up positive Improve [27] Storbeck CJ, 2013 Tibialis anterior SLK Myoblast differentiation Down Positive Improve [182] Lei, 2013 One leg of tibialis anterior MMP-13 Myoblast migration Down/Up Negative/Positive Impair/improve [183] Das, 2017 Tibialis anterior…”
BackgroundInfluentialDahiya, S., Bhatnagar, S., Hindi, S. M., Jiang, C., Paul, P. K., Kuang, S., & Kumar, A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr362 · Cited by 77
“Interestingly, both IGF-I and follistatin are the potent activators of PI3K/Akt/mTOR signaling pathway in skeletal muscle (40,41).”
BackgroundEffects of the activin A–myostatin–follistatin system on aging bone and muscle progenitor cells
Bowser, M., Herberg, S., Arounleut, P., Shi, X., Fulzele, S., Hill, W. D., Isales, C. M., & Hamrick, M. W. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2012.11.004 · Cited by 75
“Activin is thought to bind with greater affinity to the type IIA activin receptor (ActRIIA) and myostatin to the type II B receptor (ActRIIB), but both are involved in the regulation of muscle mass (Gilson et al., 2009; Lee et al., 2010).”
BackgroundAnastasilakis, A. D., Koulaxis, D., Kefala, N., Pοlyzos, S. A., Upadhyay, J., Pagkalidou, E., Economou, F. I., Anastasilakis, C. D., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.05.002 · Cited by 74
Hofmann, M., Halper, B., Oesen, S., Franzke, B., Stuparits, P., Tschan, H., Bachl, N., Strasser, E.-M., Quittan, M., Ploder, M., et al. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.02.008 · Cited by 85
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
Aoki, Y., Miyatake, S., Shimizu‐Motohashi, Y., & Takeda, S. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s110163 · Cited by 85
“112 This implies that follistatin inhibits other TGF family members in addition to myostatin to regulate muscle size.”
Mid-Gestational Gene Expression Profile in Placenta and Link to Pregnancy Complications
Uusküla-Reimand, L., Männik, J., Rull, K., Minajeva, A., Kõks, S., Vaas, P., Teesalu, P., Reimand, J., & Laan, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049248 · Cited by 92
“Other tested mid-gestation genes (BMP5, FST, ITGBL1, NEDD9, NR3C1, NRCAM, PLAGL1, SLC16A10, ZFP36L1) showed no clear trend for the difference in expression levels between complicated pregnancies and the control group (Table S8).”
InfluentialSignaling regulation during gastrulation: Insights from mouse embryos and in vitro systems
Morgani, S. M., & Hadjantonakis, A. (2019) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2019.11.011 · Cited by 79
Regulation of brown adipocyte metabolism by myostatin/follistatin signaling
Singh, R., Braga, M., & Pervin, S. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00060 · Cited by 70
“A series of genetic studies have convincingly demonstrated an essential role of Fst in skeletal muscle development (Matzuk et al., 1995; Lee et al., 2010).”
BackgroundMyostatin: Basic biology to clinical application
Esposito, P. B., Picciotto, D., Battaglia, Y., Costigliolo, F., Viazzi, F. C., & Verzola, D. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.09.006 · Cited by 83
Wetzlich, B., Nyakundi, B. B., & Yang, J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05120-y · Cited by 78
“However, the increase in muscle mass is not solely attributed to blocking MSTN, as FST also inhibits the activities of multiple TGF-β family members, some of them play a role in limiting muscle mass [76].”
Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells
Fan, H., Zhang, R., Tesfaye, D., Tholen, E., Looft, C., Hölker, M., Schellander, K., & Cinar, M. U. (2012) · Epigenetics · doi:10.4161/epi.22609 · Cited by 65
Vamvini, M. T., Aronis, K. N., Panagiotou, G., Huh, J. Y., Chamberland, J. P., Brinkoetter, M. T., Petrou, M., Christophi, C. A., Kales, S. N., Christiani, D. C., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0276 · Cited by 63
Glucocorticoids Enhance Muscle Proteolysis through a Myostatin-Dependent Pathway at the Early Stage
Wang, R., Jiao, H., Zhao, J., Wang, X., & Lin, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156225 · Cited by 74
“Moreover, follistatin, besides of function as an inhibitor of myostatin, could mediate muscle growth independently of myostatin-driven mechanisms [50, 51].”
BackgroundRNA-Seq Profiling Reveals Novel Hepatic Gene Expression Pattern in Aflatoxin B1 Treated Rats
Merrick, B. A., Phadke, D. P., Auerbach, S. S., Mav, D., Stiegelmeyer, S. M., Shah, R., & Tice, R. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061768 · Cited by 68
“The activin-follistatin system is comprised of members of the TGFb family for cell growth and differentiation and is critical for maintaining liver homeostasis and in tissue rebuilding and repair [62].”
BackgroundLee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59
“In previous studies, we showed that the function of MSTN in limiting muscle growth is redundant with that of at least one other TGF-β family member (13, 14), and several studies have implicated activin A as at least one of the key cooperating ligands (15, 16).”
Self-citationVerbrugge, S. A. J., Schönfelder, M., Becker, L., Yaghoob Nezhad, F., Hrabě de Angelis, M., & Wackerhage, H. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00553 · Cited by 56
Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis
Brown, M. L., Bonomi, L., Ungerleider, N., Zina, J., Kimura, F., Mukherjee, A., Sidis, Y., & Schneyer, A. (2011) · Obesity · doi:10.1038/oby.2011.97 · Cited by 55
“In contrast, Fst (+/−) heterozygotes have normal body weight but reduced muscle mass reflecting increased myostatin and activin bioactivity (22).”
BackgroundResultMyostatin — From the Mighty Mouse to cardiovascular disease and cachexia
Dschietzig, T. B. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.03.021 · Cited by 58
“The mere fact that unprocessed pro-myostatin appears extracellularly, but locally in skeletal muscle [35,44] may suggest that myostatin processing by furin represents a key regulatory step with regard to its bioactivity [41,45].”
BackgroundInfluentialDevelopment of Novel Activin-Targeted Therapeutics
Chen, J. L., Walton, K. L., Al-Musawi, S. L., Kelly, E. K., Qian, H., La, M., Lu, L., Lovrecz, G., Ziemann, M., Lazarus, R., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.221 · Cited by 54
Lee, C. S., Liu, M., Agha, O., Kim, H. T., Liu, X., & Feeley, B. T. (2019) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2019.09.021 · Cited by 55
Lee, C. S., Liu, M., Agha, O., Kim, H. T., Feeley, B. T., & Liu, X. (2019) · Journal of Orthopaedic Research® · doi:10.1002/jor.24558 · Cited by 58
“has shown that BAT express high levels of follistatin, a secreted glycoprotein that has high‐affinity binding for activins and myostatin and functions as an inhibitor of myostatin activity.(11,21,22) Previous work has suggested that follistatin is also a soluble mediator of functional interactions between FAP and myog…”
BackgroundRooks, D., Petricoul, O., Praestgaard, J., Bartlett, M., Laurent, D., & Roubenoff, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12639 · Cited by 54
Vamvini, M. T., Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1665 · Cited by 54
Mastaitis, J. W., Gomez, D., Raya, J. G., Li, D., Min, S., Stec, M., Kleiner, S., McWilliams, T., Altarejos, J. Y., Murphy, A. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59485-9 · Cited by 53
Pearsall, R. S., Davies, M. V., Cannell, M., Li, J., Widrick, J. J., Mulivor, A. W., Wallner, S., Troy, M., Spaits, M. S., Liharska, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47818-w · Cited by 64
Sugiyama, M., Kikuchi, A., Misu, H., Igawa, H., Ashihara, M., Kushima, Y., Honda, K., Suzuki, Y., Kawabe, Y., Kaneko, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194798 · Cited by 52
Heart failure-induced skeletal myopathy in spontaneously hypertensive rats
Damatto, R. L., Martinez, P. F., Lima, A. R. R., Cezar, M. D. M., de Campos, D. H. S., de Oliveira-Junior, S. A., Guizoni, D. M., Bonomo, C., Nakatani, B. T., Dal‐Pai‐Silva, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.063 · Cited by 58
“It has also been suggested that follistatin decreases skeletal muscle fibrosis and improves muscle healing after injury and disease [53,54].”
BackgroundIskenderian, A., Liu, N., Deng, Q., Huang, Y. L., Shen, C., Palmieri, K. J., Crooker, R., Lundberg, D. M., Kastrapeli, N., Pescatore, B., et al. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0180-z · Cited by 59
Myostatin levels in skeletal muscle of hibernating ground squirrels
Brooks, N. E., Myburgh, K. H., & Storey, K. B. (2011) · Journal of Experimental Biology · doi:10.1242/jeb.055764 · Cited by 51
de Oliveira, P. S. N., Coutinho, L. L., Tizioto, P. C., César, A. S. M., de Oliveira, G. B., Diniz, W. J. S., de Lima, A. O., Reecy, J. M., Mourão, G. B., Zerlotini, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35315-5 · Cited by 51
Han, X. H., Jin, Y.-R., Tan, L., Kosciuk, T., Lee, J., & Yoon, J. K. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01285-13 · Cited by 50
“Mice lacking the Fst gene show reduced intercostal and diaphragm muscles at birth (48), and Fst gene haploinsufficiency is associated with reduced muscle mass in adult mice (38).”
BackgroundBMPs and the muscle–bone connection
Sartori, R., & Sandri, M. (2015) · Bone · doi:10.1016/j.bone.2015.05.023 · Cited by 53
Skeletal muscle as an experimental model of choice to study tissue aging and rejuvenation
Etienne, J., Liu, C., Skinner, C. M., Conboy, M. J., & Conboy, I. M. (2020) · Skeletal Muscle · doi:10.1186/s13395-020-0222-1 · Cited by 60
Activin E–ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice
Adam, R. C., Pryce, D. S., Lee, J. S., Zhao, Y., Mintah, I. J., Min, S., Halasz, G., Mastaitis, J., Atwal, G. S., Aykul, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309967120 · Cited by 44
“While several activin/TGF β ligands are known to engage ACVR1C, the phenotypes of mice lacking these ligands do not support their roles in modulating fat distribution through ACVR1C (18, 24–27).”
Metadata
- Authors
- Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R.
- Affiliations
- Johns Hopkins University (US)
- University of Miami (US)
- Baylor College of Medicine (US)
- Fujita Health University (JP)
- University of Pennsylvania (US)
- ORCID
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2010-10-01
- Volume
- 24
- Issue
- 10
- Pages
- 1998-2008
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- PMC
- PMC2954636
- OpenAlex
- W2029816532
- Semantic Scholar
- 50765d8f8086769e58ab3497a6b5260266268e0b
- Cited by
- 273
- References
- 64
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 15 · 2023: 16 · 2022: 19 · 2021: 13 · 2020: 25 · 2019: 16 · 2018: 13 · 2017: 13 · 2016: 22 · 2015: 21 · 2014: 18 · 2013: 21 · 2012: 22
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Johns Hopkins University
- National Institutes of Health (1dp2od004515-01)
- National Institute on Aging (R01AG037193)
- National Cancer Institute (R01CA122596)
- National Institute of General Medical Sciences (R01GM092758)
- National Institute of Neurological Disorders and Stroke (K08NS055879)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR052646, R01AR060636, R01AR059685)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD032067)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
- Keywords
- follistatin, myostatin, activin A, TGF-beta superfamily, skeletal muscle mass, muscle fiber type shift, muscle remodeling, tetanic force, muscle atrophy, muscle degeneration, muscle growth
- MeSH terms
- Animals, Humans, Mice, Inbred C57BL, Muscle Contraction, Organ Size, Mice, Knockout, Muscle, Skeletal, Muscle Development, Activins, Follistatin, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.